Nabriva Therapeutics plc
NBRV
株式のランク
#39892
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
株価
$0.63
最終同期: 2023-08-29
時価総額
$284.20K
変化（1日）
-21.25%
変化（1年）
629,900.02%
国
IE
取引 Nabriva Therapeutics plc (NBRV)
カテゴリー
Healthcare
Nabriva Therapeutics plc（NBRV）のEPS
2026 時点のEPS TTM: 0
Nabriva Therapeutics plcの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Nabriva Therapeutics plcのEPS履歴（2026から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
